About Momenta Pharmaceuticals (NASDAQ:MNTA)
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE. Its biosimilars programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M834, a biosimilar of ORENCIA for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis, as well as other biosimilar candidates. The company's novel therapeutics programs include M254, a hyper-sialylated version of intravenous immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy; M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; and M230, a recombinant trivalent human IgG1 Fc multimer to block tissue damage mediated by immune complexes. It has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:MNTA
CUSIP60877T10
Phone617-491-9700
Debt
Debt-to-Equity RatioN/A
Current Ratio8.25%
Quick Ratio8.25%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$138.88 million
Price / Sales11.29
Cash FlowN/A
Price / CashN/A
Book Value$4.90 per share
Price / Book4.16
Profitability
EPS (Most Recent Fiscal Year)($1.20)
Net Income$-88,090,000.00
Net Margins-63.43%
Return on Equity-23.62%
Return on Assets-17.43%
Miscellaneous
Employees279
Outstanding Shares76,860,000
Momenta Pharmaceuticals (NASDAQ:MNTA) Frequently Asked Questions
What is Momenta Pharmaceuticals' stock symbol?
Momenta Pharmaceuticals trades on the NASDAQ under the ticker symbol "MNTA."
How were Momenta Pharmaceuticals' earnings last quarter?
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) issued its quarterly earnings data on Wednesday, February, 21st. The biotechnology company reported $0.18 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.06 by $0.12. The biotechnology company had revenue of $64.60 million for the quarter, compared to the consensus estimate of $66.59 million. Momenta Pharmaceuticals had a negative return on equity of 23.62% and a negative net margin of 63.43%. The business's revenue was up 88.9% on a year-over-year basis. During the same period in the prior year, the business earned $0.60 earnings per share. View Momenta Pharmaceuticals' Earnings History.
When is Momenta Pharmaceuticals' next earnings date?
What price target have analysts set for MNTA?
8 brokerages have issued 12-month price targets for Momenta Pharmaceuticals' shares. Their forecasts range from $6.00 to $21.00. On average, they anticipate Momenta Pharmaceuticals' stock price to reach $14.75 in the next year. View Analyst Ratings for Momenta Pharmaceuticals.
What are Wall Street analysts saying about Momenta Pharmaceuticals stock?
Here are some recent quotes from research analysts about Momenta Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Momenta’s third-quarter results were overshadowed by the disappointing results from a phase I study on the proposed biosimilar verison of Orencia. Momenta announced that M834 did not meet its primary pharmacokinetic end points in a phase I study to compare the pharmacokinetics, safety and immunogenicity of M834 to Orencia in normal healthy volunteers. Earlier, Momenta suffered a blow when the FDA approved Mylan’s generic version of Copaxone 40 mg. On the other hand, Momenta’s ANDA approval for Glatopa is contingent on the satisfactory resolution of the compliance observations stated in the warning letter issued by the FDA, resulting in a delay of approval. The warning letter will remain a major over hang on the shares till the issue is solved. Moreover, shares of the company have underperformed the industry in the last six months." (1/2/2018)
- 2. Cowen Inc analysts commented, "Glatopa sales were $23M primarily, above our estimate of $20M driven by quarterly." (5/3/2017)
Who are some of Momenta Pharmaceuticals' key competitors?
Some companies that are related to Momenta Pharmaceuticals include Spark Therapeutics (ONCE), arGEN-X BV (ARGX), China Biologic Products (CBPO), Halozyme Therapeutics (HALO), CRISPR Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Sangamo Therapeutics (SGMO), Repligen (RGEN), Acceleron Pharma (XLRN), Editas Medicine (EDIT), Atara Biotherapeutics (ATRA), Audentes Therapeutics (BOLD), DBV Technologies (DBVT), Iovance Biotherapeutics (IOVA), REGENXBIO (RGNX), Cellectis (CLLS) and Adaptimmune Therapeutics (ADAP).
Who are Momenta Pharmaceuticals' key executives?
Momenta Pharmaceuticals' management team includes the folowing people:
- Mr. Craig A. Wheeler, Pres, CEO & Exec. Director (Age 58)
- Dr. Ganesh Venkataraman Kaundinya Ph.D., Co-Founder, COO, Chief Scientific Officer & Sr. VP (Age 51)
- Mr. Scott M. Storer, Sr. VP, CFO & Principal Accounting Officer
- Mr. Bruce A. Leicher J.D., Sr. VP, Gen. Counsel and Corp. Sec. (Age 62)
- Dr. Young T. Kwon Ph.D., Sr. VP of Corp. Devel. & Strategy
Has Momenta Pharmaceuticals been receiving favorable news coverage?
News stories about MNTA stock have trended somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Momenta Pharmaceuticals earned a daily sentiment score of 0.19 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 42.41 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
How do I buy shares of Momenta Pharmaceuticals?
Shares of MNTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Momenta Pharmaceuticals' stock price today?
One share of MNTA stock can currently be purchased for approximately $20.40.
How big of a company is Momenta Pharmaceuticals?
Momenta Pharmaceuticals has a market capitalization of $1.57 billion and generates $138.88 million in revenue each year. The biotechnology company earns $-88,090,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Momenta Pharmaceuticals employs 279 workers across the globe.
How can I contact Momenta Pharmaceuticals?
Momenta Pharmaceuticals' mailing address is 675 WEST KENDALL STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-491-9700 or via email at [email protected]
MarketBeat Community Rating for Momenta Pharmaceuticals (MNTA)
MarketBeat's community ratings are surveys of what our community members think about Momenta Pharmaceuticals and other stocks. Vote "Outperform" if you believe MNTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Momenta Pharmaceuticals (NASDAQ:MNTA) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for Momenta Pharmaceuticals in the last 12 months. Their average twelve-month price target is $14.75, suggesting that the stock has a possible downside of 27.70%. The high price target for MNTA is $21.00 and the low price target for MNTA is $6.00. There are currently 1 sell rating, 6 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.00 | 2.00 | 1.89 | 1.89 |
| Ratings Breakdown: | 1 Sell Rating(s)
6 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
6 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
8 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
8 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $14.75 | $14.75 | $14.4444 | $14.4444 |
| Price Target Upside: | 27.70% downside | 9.79% downside | 2.44% upside | 4.67% upside |
Momenta Pharmaceuticals (NASDAQ:MNTA) Consensus Price Target History
Momenta Pharmaceuticals (NASDAQ:MNTA) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 2/22/2018 | Stifel Nicolaus | Upgrade | Hold -> Buy | $18.00 -> $21.00 | High |  |
| 11/1/2017 | Cowen | Set Price Target | Hold | $15.00 | N/A | |
| 10/6/2017 | Robert W. Baird | Downgrade | Buy -> Hold | $22.00 -> $15.00 | N/A | |
| 10/5/2017 | JPMorgan Chase | Reiterated Rating | Hold | $14.00 | N/A | |
| 10/5/2017 | Goldman Sachs | Reiterated Rating | Neutral | $18.00 -> $14.00 | N/A | |
| 10/4/2017 | Barclays | Reiterated Rating | Equal Weight | $17.00 -> $16.00 | High | |
| 8/3/2017 | Maxim Group | Set Price Target | Sell | $6.00 | Low | |
| 5/3/2017 | Aegis | Reiterated Rating | Hold | $17.00 | Low | |
| 2/21/2017 | Leerink Swann | Downgrade | Outperform -> Market Perform | $18.00 -> $18.00 | N/A | |
| 8/5/2016 | Brean Capital | Set Price Target | Buy | $19.00 | N/A | |
(Data available from 4/23/2016 forward)
Momenta Pharmaceuticals (NASDAQ:MNTA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Momenta Pharmaceuticals (NASDAQ MNTA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.40%
Institutional Ownership Percentage: 97.43%
Momenta Pharmaceuticals (NASDAQ MNTA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/12/2018 | Elizabeth Stoner | Director | Sell | 7,714 | $20.00 | $154,280.00 | 29,378 | |
| 4/10/2018 | Craig A. Wheeler | CEO | Sell | 43,334 | $19.00 | $823,346.00 | | |
| 4/10/2018 | Elizabeth Stoner | Director | Sell | 3,399 | $19.00 | $64,581.00 | 22,777 | |
| 3/21/2018 | Elizabeth Stoner | Director | Sell | 3,399 | $19.00 | $64,581.00 | 21,176 | |
| 2/21/2018 | Bruce Leicher | SVP | Sell | 728 | $15.90 | $11,575.20 | 171,194 | |
| 2/21/2018 | Craig A Wheeler | CEO | Sell | 3,938 | $16.46 | $64,819.48 | 239,869 | |
| 2/21/2018 | Ganesh Venkataraman Kaundinya | COO | Sell | 745 | $15.90 | $11,845.50 | 495,686 | |
| 2/14/2018 | Bruce Leicher | SVP | Sell | 4,948 | $15.22 | $75,308.56 | 176,210 | |
| 2/14/2018 | Craig A Wheeler | CEO | Sell | 18,648 | $16.14 | $300,978.72 | 258,713 | |
| 2/14/2018 | Ganesh Venkataraman Kaundinya | COO | Sell | 4,986 | $15.23 | $75,936.78 | 501,031 | |
| 2/14/2018 | Scott M. Storer | CFO | Sell | 3,972 | $15.16 | $60,215.52 | | |
| 2/12/2018 | Bruce Leicher | SVP | Sell | 309 | $16.20 | $5,005.80 | 176,210 | |
| 2/12/2018 | Craig A Wheeler | CEO | Sell | 1,773 | $16.18 | $28,687.14 | 258,713 | |
| 2/12/2018 | Ganesh Venkataraman Kaundinya | COO | Sell | 341 | $16.20 | $5,524.20 | 501,031 | |
| 2/8/2018 | Bruce Leicher | SVP | Sell | 1,861 | $16.00 | $29,776.00 | | |
| 2/8/2018 | Craig A Wheeler | CEO | Sell | 10,406 | $15.89 | $165,351.34 | 275,526 | |
| 2/8/2018 | Ganesh Venkataraman Kaundinya | COO | Sell | 1,917 | $16.00 | $30,672.00 | 492,845 | |
| 1/30/2018 | Elizabeth Stoner | Director | Sell | 16,264 | $18.00 | $292,752.00 | 32,440 | |
| 1/2/2018 | Craig A Wheeler | CEO | Sell | 35,666 | $14.11 | $503,247.26 | | |
| 12/13/2017 | Elizabeth Stoner | Director | Sell | 5,500 | $13.10 | $72,050.00 | 13,240 | |
| 11/21/2017 | Bruce Leicher | SVP | Sell | 803 | $13.15 | $10,559.45 | 172,906 | |
| 11/21/2017 | Craig A. Wheeler | CEO | Sell | 4,116 | $13.35 | $54,948.60 | | |
| 11/21/2017 | Ganesh Venkataraman Kaundinya | COO | Sell | 821 | $13.15 | $10,796.15 | 487,633 | |
| 11/10/2017 | Bruce Leicher | SVP | Sell | 355 | $13.07 | $4,639.85 | 173,322 | |
| 11/10/2017 | Craig A Wheeler | CEO | Sell | 1,852 | $13.25 | $24,539.00 | 258,602 | |
| 11/10/2017 | Ganesh Venkataraman Kaundinya | COO | Sell | 392 | $13.12 | $5,143.04 | 488,029 | |
| 9/28/2017 | Craig A Wheeler | President | Sell | 35,667 | $19.03 | $678,743.01 | 286,121 | |
| 9/1/2017 | Craig A. Wheeler | President | Sell | 20,367 | $17.00 | $346,239.00 | | |
| 8/21/2017 | Bruce Leicher | SVP | Sell | 802 | $15.20 | $12,190.40 | 174,064 | |
| 8/21/2017 | Craig A Wheeler | President | Sell | 4,116 | $15.07 | $62,028.12 | 269,231 | |
| 8/21/2017 | Ganesh Venkataraman Kaundinya | VP | Sell | 821 | $15.20 | $12,479.20 | 488,846 | |
| 8/10/2017 | Bruce Leicher | SVP | Sell | 350 | $16.60 | $5,810.00 | | |
| 8/10/2017 | Craig A. Wheeler | President | Sell | 16,953 | $16.94 | $287,183.82 | | |
| 8/10/2017 | Ganesh Venkataraman Kaundinya | VP | Sell | 387 | $16.60 | $6,424.20 | 489,242 | |
| 8/2/2017 | Craig A Wheeler | President | Sell | 200 | $17.00 | $3,400.00 | 279,961 | |
| 5/22/2017 | Bruce Leicher | SVP | Sell | 859 | $14.80 | $12,713.20 | | |
| 5/19/2017 | Craig A Wheeler | President | Sell | 4,116 | $15.83 | $65,156.28 | 281,919 | |
| 5/19/2017 | Ganesh Venkataraman Kaundinya | VP | Sell | 821 | $15.90 | $13,053.90 | | |
| 5/10/2017 | Bruce Leicher | SVP | Sell | 347 | $16.00 | $5,552.00 | 175,205 | |
| 5/10/2017 | Craig A. Wheeler | President | Sell | 1,852 | $15.77 | $29,206.04 | | |
| 5/10/2017 | Ganesh Venkataraman Kaundinya | VP | Sell | 384 | $16.00 | $6,144.00 | 490,453 | |
| 12/15/2016 | Richard P Shea | CFO | Sell | 9,799 | $15.00 | $146,985.00 | 121,972 | |
| 12/9/2016 | Richard P Shea | CFO | Sell | 1,451 | $15.00 | $21,765.00 | 129,705 | |
| 11/22/2016 | Bruce Leicher | SVP | Sell | 1,030 | $13.66 | $14,069.80 | | |
| 11/22/2016 | Craig A. Wheeler | President | Sell | 5,880 | $13.68 | $80,438.40 | | |
| 11/22/2016 | James M Roach | VP | Sell | 1,091 | $13.67 | $14,913.97 | 156,056 | |
| 11/22/2016 | Richard P Shea | CFO | Sell | 971 | $13.67 | $13,273.57 | 131,731 | |
| 8/22/2016 | Bruce Leicher | SVP | Sell | 1,030 | $12.05 | $12,411.50 | 183,566 | |
| 8/22/2016 | Craig A. Wheeler | President | Sell | 5,880 | $12.02 | $70,677.60 | | |
| 8/22/2016 | James M Roach | VP | Sell | 1,091 | $12.05 | $13,146.55 | 157,147 | |
| 8/22/2016 | Richard P Shea | CFO | Sell | 972 | $12.05 | $11,712.60 | 132,703 | |
| 5/20/2016 | Bruce Leicher | SVP | Sell | 1,000 | $10.40 | $10,400.00 | 184,576 | |
| 5/20/2016 | Craig A Wheeler | President | Sell | 5,880 | $10.18 | $59,858.40 | 349,521 | |
| 5/20/2016 | Ganesh Venkataraman Kaundinya | VP | Sell | 1,050 | $10.18 | $10,689.00 | 456,765 | |
| 5/20/2016 | Richard P Shea | CFO | Sell | 973 | $10.18 | $9,905.14 | 133,675 | |
| 5/19/2016 | John E Bishop | VP | Sell | 784 | $10.20 | $7,996.80 | 157,640 | |
| 4/19/2016 | John E Bishop | VP | Sell | 2,843 | $9.57 | $27,207.51 | 160,880 | |
| 2/23/2016 | John E Bishop | VP | Sell | 329 | $9.70 | $3,191.30 | 107,188 | |
| 2/22/2016 | Bruce Leicher | SVP | Sell | 227 | $9.65 | $2,190.55 | 131,188 | |
| 2/22/2016 | Craig A Wheeler | President | Sell | 1,688 | $9.95 | $16,795.60 | 244,342 | |
| 2/22/2016 | John E Bishop | VP | Sell | 2,848 | $9.66 | $27,511.68 | 109,859 | |
| 2/19/2016 | Bruce Leicher | SVP | Sell | 2,000 | $9.64 | $19,280.00 | 132,991 | |
| 2/19/2016 | Craig A Wheeler | President | Sell | 9,844 | $9.37 | $92,238.28 | 253,905 | |
| 2/19/2016 | John E. Bishop | VP | Sell | 357 | $10.28 | $3,669.96 | 110,263 | |
| 2/19/2016 | Richard P Shea | CFO | Sell | 1,823 | $9.64 | $17,573.72 | 141,924 | |
| 2/18/2016 | Bruce Leicher | SVP | Sell | 337 | $10.49 | $3,535.13 | 133,415 | |
| 2/18/2016 | James M Roach | VP | Sell | 272 | $10.49 | $2,853.28 | 107,269 | |
| 2/18/2016 | Richard P Shea | CFO | Sell | 183 | $10.49 | $1,919.67 | 142,328 | |
| 2/17/2016 | Craig A Wheeler | President | Sell | 1,688 | $11.30 | $19,074.40 | 255,874 | |
| 12/11/2015 | Michael Franken | Insider | Sell | 520 | $15.84 | $8,236.80 | 37,968 | |
| 11/20/2015 | Craig A Wheeler | President | Sell | 1,766 | $17.86 | $31,540.76 | 200,844 | |
| 11/19/2015 | Craig A Wheeler | President | Sell | 2,061 | $18.05 | $37,201.05 | 202,610 | |
| 11/17/2015 | Craig A Wheeler | President | Sell | 1,766 | $17.70 | $31,258.20 | 204,671 | |
| 11/5/2015 | Craig A. Wheeler | President | Sell | 51,667 | $18.00 | $930,006.00 | 206,437 | |
| 8/20/2015 | Craig A Wheeler | President | Sell | 1,766 | $22.28 | $39,346.48 | 212,719 | |
| 8/19/2015 | Craig A Wheeler | President | Sell | 2,061 | $22.02 | $45,383.22 | 214,485 | |
| 8/19/2015 | James M. Roach | VP | Sell | 7,011 | $22.09 | $154,872.99 | 92,079 | |
| 8/18/2015 | James M Roach | VP | Sell | 6,812 | $21.80 | $148,501.60 | | |
| 8/17/2015 | Craig A Wheeler | President | Sell | 1,766 | $21.77 | $38,445.82 | 216,546 | |
| 7/15/2015 | Elizabeth Stoner | Director | Sell | 4,570 | $22.35 | $102,139.50 | | |
| 6/19/2015 | John E Bishop | VP | Sell | 21,274 | $25.50 | $542,487.00 | | |
| 6/18/2015 | Bruce Leicher | SVP | Sell | 20,000 | $23.00 | $460,000.00 | | |
| 6/18/2015 | Craig A Wheeler | President | Sell | 155,000 | $24.20 | $3,751,000.00 | | |
| 6/18/2015 | John E Bishop | VP | Sell | 36,313 | $23.58 | $856,260.54 | | |
| 6/4/2015 | Craig A Wheeler | President | Sell | 103,333 | $22.00 | $2,273,326.00 | | |
| 6/1/2015 | Bruce Leicher | SVP | Sell | 40,000 | $21.00 | $840,000.00 | | |
| 6/1/2015 | James M Roach | VP | Sell | 25,000 | $21.70 | $542,500.00 | | |
| 5/20/2015 | Craig A Wheeler | President | Sell | 1,766 | $19.68 | $34,754.88 | | |
| 5/19/2015 | Craig A Wheeler | President | Sell | 2,061 | $19.67 | $40,539.87 | | |
| 4/23/2015 | Craig A Wheeler | President | Sell | 51,667 | $20.00 | $1,033,340.00 | | |
| 4/23/2015 | Ganesh Venkataraman Kaundinya | VP | Sell | 34,000 | $19.95 | $678,300.00 | | |
| 4/20/2015 | Craig A Wheeler | President | Sell | 6,269 | $18.75 | $117,543.75 | | |
| 4/17/2015 | Bruce Leicher | SVP | Sell | 52,910 | $19.52 | $1,032,803.20 | | |
| 4/16/2015 | James M Roach | VP | Sell | 50,000 | $18.70 | $935,000.00 | | |
| 3/16/2015 | Richard P Shea | CFO | Sell | 23,093 | $15.10 | $348,704.30 | | |
| 3/5/2015 | Richard P Shea | CFO | Sell | 23,364 | $14.90 | $348,123.60 | | |
| 2/24/2015 | Craig A Wheeler | President | Sell | 2,110 | $13.52 | $28,527.20 | | |
| 2/20/2015 | Bruce Leicher | SVP | Sell | 1,891 | $12.97 | $24,526.27 | | |
| 2/20/2015 | Craig A Wheeler | President | Sell | 9,563 | $13.49 | $129,004.87 | | |
| 2/20/2015 | John E Bishop | VP | Sell | 1,768 | $12.97 | $22,930.96 | | |
| 2/20/2015 | Richard P Shea | CFO | Sell | 1,812 | $12.97 | $23,501.64 | | |
| 2/18/2015 | Craig A Wheeler | President | Sell | 1,688 | $11.91 | $20,104.08 | | |
| 12/15/2014 | Bennett M Shapiro | Director | Sell | 5,800 | $12.19 | $70,702.00 | | |
| 12/11/2014 | Michael Franken | Insider | Sell | 2,047 | $12.29 | $25,157.63 | | |
| 12/1/2014 | Bennett M Shapiro | Director | Sell | 9,903 | $12.00 | $118,836.00 | | |
| 11/28/2014 | Bennett M Shapiro | Director | Sell | 1,897 | $12.00 | $22,764.00 | | |
| 11/25/2014 | Craig A Wheeler | President | Sell | 2,210 | $11.59 | $25,613.90 | | |
| 11/20/2014 | Craig A Wheeler | President | Sell | 1,768 | $11.10 | $19,624.80 | | |
| 11/17/2014 | Craig A Wheeler | President | Sell | 1,768 | $10.58 | $18,705.44 | | |
| 10/3/2014 | Bennett M Shapiro | Director | Sell | 3,723 | $12.00 | $44,676.00 | | |
| 9/12/2014 | Peter Barton Hutt | Director | Sell | 3,640 | $11.42 | $41,568.80 | | |
| 8/25/2014 | Craig A Wheeler | President | Sell | 2,209 | $11.45 | $25,293.05 | | |
| 8/20/2014 | Craig A Wheeler | President | Sell | 1,768 | $11.54 | $20,402.72 | | |
| 8/15/2014 | Bennett M Shapiro | Director | Sell | 3,722 | $12.00 | $44,664.00 | | |
| 8/15/2014 | Craig A Wheeler | President | Sell | 1,768 | $11.75 | $20,774.00 | | |
| 8/13/2014 | Bennett M Shapiro | Director | Sell | 3,721 | $12.00 | $44,652.00 | | |
| 5/23/2014 | Craig A Wheeler | President | Sell | 2,110 | $12.06 | $25,446.60 | | |
| 5/20/2014 | Craig Wheeler | President | Sell | 1,688 | $12.08 | $20,391.04 | 376,164 | |
| 5/15/2014 | Craig Wheeler | President | Sell | 1,687 | $11.09 | $18,708.83 | 377,852 | |
| 2/25/2014 | Craig Wheeler | President | Sell | 2,109 | $17.47 | $36,844.23 | 379,539 | |
| 2/24/2014 | John Bishop | VP | Sell | 1,038 | $17.67 | $18,341.46 | 111,621 | |
| 2/19/2014 | Craig Wheeler | President | Sell | 3,797 | $17.90 | $67,966.30 | 388,398 | |
| 2/12/2014 | Ganesh Venkataraman Kaundinya | VP | Sell | 33,000 | $17.96 | $592,680.00 | 346,129 | |
| 1/9/2014 | John Bishop | VP | Sell | 27,159 | $19.50 | $529,600.50 | 93,780 | |
| 11/25/2013 | Bruce Leicher | SVP | Sell | 13,492 | $18.00 | $242,856.00 | 108,975 | |
| 11/25/2013 | Craig Wheeler | President | Sell | 2,215 | $17.77 | $39,360.55 | 322,195 | |
| 11/25/2013 | Ganesh Venkataraman Kaundinya | VP | Sell | 33,211 | $18.02 | $598,462.22 | 391,129 | |
| 11/19/2013 | Craig Wheeler | President | Sell | 2,215 | $17.17 | $38,031.55 | 324,410 | |
| 11/15/2013 | Craig Wheeler | President | Sell | 1,772 | $16.88 | $29,911.36 | 326,625 | |
| 10/11/2013 | John Bishop | VP | Sell | 5,247 | $15.46 | $81,118.62 | 94,618 | |
| 8/23/2013 | Craig Wheeler | President | Sell | 2,109 | $14.90 | $31,424.10 | 328,397 | |
| 8/20/2013 | Craig Wheeler | President | Sell | 2,109 | $14.47 | $30,517.23 | 330,506 | |
| 8/15/2013 | Craig Wheeler | President | Sell | 1,688 | $15.43 | $26,045.84 | 332,615 | |
| 7/26/2013 | Richard P Shea | CFO | Sell | 30,000 | $16.61 | $498,300.00 | | |
| 6/27/2013 | Richard P Shea | CFO | Sell | 10,522 | $14.61 | $153,726.42 | | |
| 6/19/2013 | Richard P Shea | CFO | Sell | 21,550 | $14.61 | $314,845.50 | | |
| 5/23/2013 | Craig A Wheeler | President | Sell | 2,109 | $13.03 | $27,480.27 | | |
| 5/21/2013 | Craig A Wheeler | President | Sell | 2,109 | $12.83 | $27,058.47 | | |
| 5/15/2013 | Craig A Wheeler | President | Sell | 1,687 | $13.33 | $22,487.71 | | |
| 3/5/2013 | Elizabeth Stoner | Director | Sell | 2,040 | $14.00 | $28,560.00 | | |
| 2/15/2013 | Bruce Leicher | SVP | Sell | 1,040 | $12.26 | $12,750.40 | | |
(Data available from 1/1/2013 forward)
Momenta Pharmaceuticals (NASDAQ MNTA) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Momenta Pharmaceuticals (MNTA) to Release Earnings on Monday
www.americanbankingnews.com - April 23 at 6:36 AM |
| Momenta Pharmaceuticals, Inc. (MNTA) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 18 at 9:40 AM |
| Momenta Pharmaceuticals (MNTA) Rating Reiterated by Stifel Nicolaus
www.americanbankingnews.com - April 13 at 9:27 PM |
| Maxim Group Reiterates $6.00 Price Target for Momenta Pharmaceuticals (MNTA)
www.americanbankingnews.com - April 13 at 7:15 PM |
| Elizabeth Stoner Sells 7,714 Shares of Momenta Pharmaceuticals, Inc. (MNTA) Stock
www.americanbankingnews.com - April 13 at 7:11 PM |
| Momenta Pharmaceuticals, Inc. (MNTA) Director Sells $64,581.00 in Stock
www.americanbankingnews.com - April 12 at 7:35 PM |
| Elizabeth Stoner Sells 3,399 Shares of Momenta Pharmaceuticals, Inc. (MNTA) Stock
www.americanbankingnews.com - April 12 at 7:35 PM |
| Momenta Pharmaceuticals, Inc. (MNTA) CEO Sells $823,346.00 in Stock
www.americanbankingnews.com - April 12 at 7:17 PM |
| Momenta Pharmaceuticals' (MNTA) Hold Rating Reiterated at Stifel Nicolaus
www.americanbankingnews.com - April 8 at 12:40 AM |
| Momenta Pharmaceuticals (MNTA) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - April 5 at 12:31 AM |
| Momenta Pharmaceuticals (MNTA) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - April 3 at 11:31 PM |
| Momenta Pharmaceuticals (MNTA) Given a $15.00 Price Target at Cowen
www.americanbankingnews.com - April 2 at 4:16 PM |
 | How Did Sandoz Perform in 4Q17 and Fiscal 2017?
finance.yahoo.com - April 2 at 9:57 AM |
| Momenta Pharmaceuticals (MNTA) Upgraded by BidaskClub to Buy
www.americanbankingnews.com - March 30 at 2:19 PM |
| Analyzing Momenta Pharmaceuticals (MNTA) and Gemphire Therapeutics (GEMP)
www.americanbankingnews.com - March 29 at 11:06 PM |
| Momenta Pharmaceuticals (MNTA) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - March 27 at 4:34 PM |
| Momenta Pharmaceuticals (MNTA) Downgraded by BidaskClub
www.americanbankingnews.com - March 27 at 3:28 PM |
| Momenta Pharmaceuticals, Inc. (MNTA) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - March 24 at 9:56 AM |
| Sectoral Asset Management Inc Grows Stake in Momenta Pharmaceuticals, Inc. (MNTA)
www.americanbankingnews.com - March 5 at 3:35 PM |
| Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences
finance.yahoo.com - March 5 at 9:44 AM |
| Reviewing Global Blood Therapeutics (GBT) and Momenta Pharmaceuticals (MNTA)
www.americanbankingnews.com - March 5 at 3:08 AM |
| Momenta Pharmaceuticals, Inc. (MNTA) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - February 27 at 12:32 PM |
| Momenta Pharmaceuticals Inc (MNTA) Files 10-K for the Fiscal Year Ended on December 31, 2017
finance.yahoo.com - February 26 at 4:57 PM |
| Momenta Pharmaceuticals (MNTA) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - February 25 at 4:54 PM |
| Momenta Pharmaceuticals (MNTA) Upgraded to "Buy" by Stifel Nicolaus
www.americanbankingnews.com - February 25 at 2:06 PM |
| Momenta Pharmaceuticals (MNTA) Upgraded to "Hold" by ValuEngine
www.americanbankingnews.com - February 25 at 12:34 AM |
| KBC Group NV Boosts Stake in Momenta Pharmaceuticals, Inc. (MNTA)
www.americanbankingnews.com - February 24 at 5:24 AM |
| Momenta Pharmaceuticals, Inc. (MNTA) SVP Sells $11,575.20 in Stock
www.americanbankingnews.com - February 23 at 3:40 PM |
| Momenta Pharmaceuticals, Inc. (MNTA) COO Ganesh Venkataraman Kaundinya Sells 745 Shares
www.americanbankingnews.com - February 23 at 3:40 PM |
| Momenta Pharmaceuticals, Inc. (MNTA) CEO Craig A. Wheeler Sells 3,938 Shares
www.americanbankingnews.com - February 23 at 3:22 PM |
| Stifel: Momenta Pharma's Autoimmune Pipeline Potential Makes It A Buy
finance.yahoo.com - February 23 at 9:25 AM |
| Momenta's (MNTA) Earnings & Revenues Surpass Estimates in Q4
finance.yahoo.com - February 22 at 4:49 PM |
| Momenta Pharmaceuticals Wraps Up a Bleak Year
finance.yahoo.com - February 22 at 4:49 PM |
| Today’s Research Reports on Stocks to Watch: Momenta Pharmaceuticals and Nektar Therapeutics
finance.yahoo.com - February 22 at 9:18 AM |
 | Teva's Problems Continue to Mount With No Relief in Sight
www.msn.com - February 21 at 4:40 PM |
| Momenta Pharmaceuticals (MNTA) Releases Quarterly Earnings Results, Beats Estimates By $0.36 EPS
www.americanbankingnews.com - February 21 at 11:24 AM |
| Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - February 21 at 9:35 AM |
| Momenta Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - February 21 at 9:35 AM |
| Momenta posts 4Q profit
finance.yahoo.com - February 21 at 9:35 AM |
| BidaskClub Upgrades Momenta Pharmaceuticals (MNTA) to Buy
www.americanbankingnews.com - February 19 at 4:02 PM |
| Biohaven Pharmaceutical (BHVN) versus Momenta Pharmaceuticals (MNTA) Head to Head Survey
www.americanbankingnews.com - February 17 at 12:34 PM |
| Momenta Pharmaceuticals, Inc. (MNTA) CFO Scott M. Storer Sells 3,972 Shares
www.americanbankingnews.com - February 14 at 10:18 PM |
| Craig A. Wheeler Sells 1,773 Shares of Momenta Pharmaceuticals, Inc. (MNTA) Stock
www.americanbankingnews.com - February 14 at 10:18 PM |
| Momenta Pharmaceuticals, Inc. (MNTA) COO Sells $75,936.78 in Stock
www.americanbankingnews.com - February 14 at 9:58 PM |
| Momenta Pharmaceuticals, Inc. (MNTA) SVP Sells $75,308.56 in Stock
www.americanbankingnews.com - February 14 at 9:58 PM |
| Momenta Pharmaceuticals, Inc. (MNTA) CEO Sells $300,978.72 in Stock
www.americanbankingnews.com - February 14 at 9:40 PM |
| Teva Pharmaceutical Industries Ltd -- Moody's says launch of second generic version of Copaxone 40mg is credit negative for Teva
finance.yahoo.com - February 13 at 4:27 PM |
| Ganesh Venkataraman Kaundinya Sells 1,917 Shares of Momenta Pharmaceuticals, Inc. (MNTA) Stock
www.americanbankingnews.com - February 12 at 7:08 PM |
| Momenta Pharmaceuticals, Inc. (MNTA) SVP Sells $29,776.00 in Stock
www.americanbankingnews.com - February 12 at 7:08 PM |
| Momenta Pharmaceuticals, Inc. (MNTA) CEO Craig A. Wheeler Sells 10,406 Shares
www.americanbankingnews.com - February 12 at 6:46 PM |
Momenta Pharmaceuticals (NASDAQ:MNTA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Momenta Pharmaceuticals (NASDAQ:MNTA) Income Statement, Balance Sheet and Cash Flow Statement
Momenta Pharmaceuticals (NASDAQ MNTA) Stock Chart for Monday, April, 23, 2018
Loading chart…
